Skip to content
bucindolol

Structure via PubChem · Public domain (PubChem)

EntityQ4982756· pop 7· linked from 562 articles

bucindolol

Sign in to save

Bucindolol is a non-selective beta blocker with additional weak alpha-blocking properties and intrinsic sympathomimetic activity in some model systems but not in human hearts. It was under review by the FDA in the United States for the treatment of heart failure in 2009, but was rejected due to issues pertaining to integrity of data submitted.

Chemical data

Formula
C22H25N3O2
Molecular weight
363.5 g/mol
IUPAC name
2-[2-hydroxy-3-[[1-(1H-indol-3-yl)-2-methylpropan-2-yl]amino]propoxy]benzonitrile
SMILES
CC(C)(CC1=CNC2=CC=CC=C21)NCC(COC3=CC=CC=C3C#N)O
InChIKey
FBMYKMYQHCBIGU-UHFFFAOYSA-N
XLogP
3.3
Polar surface area
81.1 Ų
H-bond donors
3
H-bond acceptors
4
Formal charge
0

via PubChem

Drug data · ChEMBL

Max clinical phase
Phase 2
Molecule type
Small molecule

via ChEMBL · EBI

Wikidata facts

Mass
363.195
Show 2 more facts
chemical formula
C₂₂H₂₅N₃O₂
canonical SMILES
CC(C)(CC1=CNC2=CC=CC=C21)NCC(COC3=CC=CC=C3C#N)O
Sources (2)

via Wikidata · CC0

~1 min read

Encyclopedic overview

3 sections
Contents
  • Synthesis
  • See also
  • References

Bucindolol is a non-selective beta blocker with additional weak alpha-blocking properties and intrinsic sympathomimetic activity in some model systems but not in human hearts. It was under review by the FDA in the United States for the treatment of heart failure in 2009, but was rejected due to issues pertaining to integrity of data submitted.

==Synthesis== 500px|class=skin-invert-image

Excerpted from Wikipedia’s “bucindolol” article, available under the CC BY-SA 4.0 licence.

Available in 7 languages

via Wikidata sitelinks · CC0